Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors

Cancer Science

Volumn 99, Issue 7, 2008, Pages 1348-1354

  Kim, Jin C ^a,b   Cho, Young K ^a,b   Roh, Seon A ^a,b   Yu, Chang S ^a   Gong, Gyungyub ^a   Jang, Se J ^a   Kim, Seon Y ^c   Kim, Yong S ^c  

^a University of Ulsan   (South Korea)

^b Asan Institute for Life Sciences   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; AXIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; GLUTAMIC ACID; PROTEIN P53; RAF PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; VALINE; WNT PROTEIN;

ADULT; AGED; ARTICLE; CANCER INVASION; CLINICAL FEATURE; COLLOID CARCINOMA; COLON CANCER; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; COLORECTAL SURGERY; CONTROLLED STUDY; EXCISION REPAIR; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; RECURRENCE RISK; STATISTICAL SIGNIFICANCE; TUMOR GROWTH; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; GENES, APC; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; RAF KINASES;

EID: 44449160042     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00819.x     Document Type: Article

References (43)

1. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319: 525-32.
2. Smith G, Carey FA, Beattie J et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci USA 2002; 99: 9433-8.
3. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 1999; 36: 801 -18.
4. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29.
5. Haydon AM, Jass JR. Emerging pathways in colorectal-cancer development. Lancet Oncol 2002; 3: 83-8.
6. Iacopetta BJ, Welch J, Soong R, House AK, Zhou XP, Hamelin R. Mutation of the transforming growth factor-β type II receptor gene in right-sided colorectal cancer: Relationship to clinicopathological features and genetic alterations. J Pathol 1998; 184: 390-5.
7. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001; 344: 1196-206.
8. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999; 59: 3379-86.
9. American Joint Committee on Cancer. Cancer Staging Handbook. (ed. FL Greene et al.) 2002; Springer: New York.
10. Kim JC, Roh SA, Lee KH, Namgung H, Kim JR, Kim JS. Genetic and pathologic changes associated with lymphovascular invasion of colorectal adenocarcinoma. Clin Exp Metastasis 2005; 22: 421-8.
11. Lüchtenborg M, Weijenberg MP, Wark PA et al. Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study. BMC Cancer 2005; 5: 160.
12. Kim JC, Ka IH, Lee YM et al. MYH, OGG1, MTH1, and APC alterations involved in the colorectal tumorigenesis of Korean patients with multiple adenomas. Virchows Arch 2007; 450: 311-19.
13. Nagasaka T, Sasamoto H, Notohara K et al. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation. J Clin Oncol 2004; 22: 4584-94.
14. Yamanoshita O, Kubota T, Hou J et al. DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues. Int J Cancer 2005; 114: 74-9.
15. Thorstensen L, Lind GE, Løvig T et al. Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia 2005; 7: 99-108.
16. Kim JC, Koo KH, Roh SA et al. Genetic and epigenetic changes in the APC gene in sporadic colorectal carcinoma with synchronous adenoma. Int J Colorectal Dis 2003; 18: 203-9.
17. Watson AJ, Merritt AJ, Jones LS et al. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 1996; 73: 889-95.
18. Macias-Silva M, Abdollah S, Hoodless P, Pirone R, Attisano L, Wrana JL. MADR2 is a substrate of the TGF β receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87: 1215-24.
19. Akiyama T. Wnt/β-catenin signaling. Cytokine Growth Factor Rev 2000; 11: 273-82.
20. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology 2002; 123: 862-76.
21. Ogino S, Kawasaki T, Ogawa A, Kirkner GJ, Loda M, Fuchs CS. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Hum Pathol 2007; 38: 614-20.
22. Sugai T, Habano W, Jiao YF et al. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: Proposal for new molecular profile of colorectal carcinomas. J Mol Diagn 2006; 8: 193-201.
23. Breivik J, Lothe RA, Meling GI, Rognum TO, Børresen-Dale AL, Gaudernack G. Different genetic pathways to proximal and distal colorectal cancer influenced by sex-related factors. Int J Cancer 1997; 74: 664-9.
24. Kim JC, Lee KH, Ka IH et al. Characterization of mutator phenotype in familial colorectal cancer patients not fulfilling Amsterdam criteria. Clin Cancer Res 2004; 10: 6159-68.
25. Margison GP, Santibanez-Koref MF. O6-alkylguanine-DNA alkyltransferase: role in carcinogenesis and chemotherapy. Bioessays 2002; 24: 255-66.
26. Bertholon J, Wang Q, Galmarini CM, Puisieux A. Mutational targets in colorectal cancer cells with microsatellite instability. Fam Cancer 2006; 5: 29-34.
27. Abdel-Rahman WM, Ollikainen M, Kariola R et al. Comprehensive characteriz-ation of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene 2005; 24: 1542-51.
28. Dong X, Seelan RS, Qian C, Mai M, Liu W. Genomic structure, chromosome mapping and expression analysis of the human AXIN2 gene. Cytogenet Cell Genet 2001; 93: 26-8.
29. Jung B, Doctolero RT, Tajima A et al. Loss of activin receptor type 2 protein expression in microsatellite unstable colon cancers. Gastroenterology 2004; 126: 654-9.
30. Domingo E, Espín E, Armengol M et al. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004; 39: 138-42.
31. Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 2007; 25: 767-72.
32. Attisano L, LabbéE. TGFβ and Wnt pathway cross-talk. Cancer Metastasis Rev 2004; 23: 53-61.
33. Grady WM, Willis JE, Trobridge P et al. Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations. Int J Cancer 2006; 118: 600-8.
34. Sansom OJ, Reed KR, Hayes AJ et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004; 18: 1385-90.
35. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
36. Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-62.
37. Tanaka T, Watanabe T, Kazama Y et al. Loss of Smad4 protein expression and 18qLOH as molecular markers indicating lymph node metastasis in colorectal cancera study matched for tumor depth and pathology. J Surg Oncol 2008; 97: 69-73.
38. Muñoz NM, Upton M, Rojas A et al. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res 2006; 66: 9837-44.
39. Alberici P, de Pater E, Cardoso J et al. Aneuploidy arises at early stages of Apc-driven intestinal tumorigenesis and pinpoints conserved chromosomal loci of allelic imbalance between mouse and human. Am J Pathol 2007; 170: 377-87.
40. Zhang H, Richards B, Wilson T et al. Apoptosis induced by overexpression of hMSH2 or hMLH1. Cancer Res 1999; 59: 3021-7.
41. Fang JY, Richardson BC. The MAPK signalling pathways and colorectal cancer. Lancet Oncol 2005; 6: 322-7.
42. Kodach LL, Bleuming SA, Musler AR et al. The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. Cancer 2008; 112: 300-6.
43. Mariadason JM, Bordonaro M, Aslam F et al. Down-regulation of β-catenin TCF signaling is linked to colonic epithelial cell differentiation. Cancer Res 2001; 61: 3465-71.